Article Text

Download PDFPDF
Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma
  1. J. A. Rauh-Hain and
  2. R. T. Penson
  1. Division of Clinical Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts
  1. Address correspondence and reprint requests to: Richard T. Penson, M.R.C.P., M.D., Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Yawkey 9066, 55 Fruit Street, Boston, Massachusetts 02114-2617. Email: rpenson{at}


Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC). Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with proven antitumor activity in RCC and a rational biological option for treatment of OCCA. A 60-year-old woman presented with recurrent and refractory stage IA OCCA, after 9 years of remission. Sunitinib was initiated as fifth-line chemotherapy, associated with cystic degeneration of liver metastasis and a short downward trend in her CA125 level. Recurrent and refractory OCCA may respond to Sunitinib. Clinical trials are needed to objectively confirm these findings, as benefit may be limited in patients with extensively pretreated tumors

  • ovarian clear cell adenocarcinoma
  • Sunitinib
  • angiogenesis
  • VEGF

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.